MX2020003947A - Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. - Google Patents

Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.

Info

Publication number
MX2020003947A
MX2020003947A MX2020003947A MX2020003947A MX2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A MX 2020003947 A MX2020003947 A MX 2020003947A
Authority
MX
Mexico
Prior art keywords
antibody
pharmaceutical composition
same
cancer treatment
cancer
Prior art date
Application number
MX2020003947A
Other languages
English (en)
Inventor
Eun Jung Song
Hye Ji Choi
Ki Su Kim
Jun Hong Jeong
Hyung Kwon Lim
Jong Wha Won
Ae Rin Yoon
Ok Jae Lim
Yun Jung Lee
Original Assignee
Green Cross Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Green Cross Corp filed Critical Green Cross Corp
Publication of MX2020003947A publication Critical patent/MX2020003947A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

La presente invención se refiere a un anticuerpo anti-CD3 y a una composición farmacéutica para el tratamiento del cáncer que comprende el mismo. El anticuerpo de acuerdo con la presente invención tiene una alta afinidad y especificidad por CD3 y, por lo tanto, puede usarse eficazmente en la prevención o el tratamiento del cáncer.
MX2020003947A 2017-10-20 2018-10-22 Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo. MX2020003947A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020170136564A KR101973060B1 (ko) 2017-10-20 2017-10-20 항-cd3 항체 및 이를 포함하는 암 치료용 약학적 조성물
PCT/KR2018/012492 WO2019078697A2 (ko) 2017-10-20 2018-10-22 항" cd3항체 및 이를포함하는 암치료용 약학적 조성물

Publications (1)

Publication Number Publication Date
MX2020003947A true MX2020003947A (es) 2020-08-03

Family

ID=66173409

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020003947A MX2020003947A (es) 2017-10-20 2018-10-22 Anticuerpo anti-cd3 y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.

Country Status (13)

Country Link
US (2) US11498965B2 (es)
EP (1) EP3699192A4 (es)
JP (1) JP7024072B2 (es)
KR (1) KR101973060B1 (es)
CN (1) CN111315779B (es)
AU (1) AU2018353787B2 (es)
BR (1) BR112020007770A2 (es)
CA (1) CA3077007C (es)
EA (1) EA202090944A1 (es)
IL (1) IL274007B2 (es)
MX (1) MX2020003947A (es)
SG (1) SG11202003273PA (es)
WO (1) WO2019078697A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2020236797A1 (en) * 2019-05-21 2020-11-26 Novartis Ag Variant cd58 domains and uses thereof
CN118994397A (zh) 2019-05-21 2024-11-22 诺华股份有限公司 针对bcma的三特异性结合分子及其用途
UY38701A (es) 2019-05-21 2020-12-31 Novartis Ag Moléculas de unión a cd19, conjugados, composiciones que las comprenden y usos de las mismas
AU2021333577B2 (en) 2020-08-25 2025-09-11 Gilead Sciences, Inc. Multi-specific antigen binding molecules targeting HIV and methods of use
EP4223777A4 (en) * 2020-09-29 2025-01-08 Fortvita Biologics (Singapore) Pte. Ltd. ANTI-CD3 ANTIBODY AND ITS USES
KR20240109605A (ko) * 2021-09-13 2024-07-11 산둥심시어 바이오파마슈티칼 씨오., 엘티디. 항-인간 cd3 항체 및 이의 응용
KR102939282B1 (ko) 2023-05-03 2026-03-16 아주대학교산학협력단 IL-5Rα×CD3ε T 세포 관여 이중 특이 항체 및 이의 용도
WO2026006494A1 (en) * 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-cd3 antibodies and uses thereof
WO2026006492A2 (en) 2024-06-25 2026-01-02 Ypsilon Therapeutics, Inc. Anti-prame/hla-a2 antibodies and uses thereof
WO2026006495A1 (en) 2024-06-25 2026-01-02 Alloy Therapeutics, Inc. Anti-wt1/hla-a2 antibody and uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003243138A1 (en) * 2002-03-26 2003-10-13 Trubion Pharmaceuticals, Inc. Activation of tumor-reactive lymphocytes via antibodies or genes recognizing cd3 or 4-1bb
JP5686953B2 (ja) 2005-10-11 2015-03-18 アムゲン リサーチ （ミュンヘン） ゲーエムベーハー 交差種特異的（ｃｒｏｓｓ−ｓｐｅｃｉｅｓ−ｓｐｅｃｉｆｉｃ）抗体を含む組成物および該組成物の使用
WO2012158818A2 (en) * 2011-05-16 2012-11-22 Fabion Pharmaceuticals, Inc. Multi-specific fab fusion proteins and methods of use
US9587021B2 (en) * 2011-05-21 2017-03-07 Macrogenics, Inc. CD3-binding molecules capable of binding to human and non-human CD3
JOP20200236A1 (ar) * 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
KR102363220B1 (ko) * 2013-07-05 2022-02-15 젠맵 에이/에스 인간화 또는 키메라 cd3 항체
EP2839842A1 (en) * 2013-08-23 2015-02-25 MacroGenics, Inc. Bi-specific monovalent diabodies that are capable of binding CD123 and CD3 and uses thereof
MX379030B (es) * 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
KR20170010863A (ko) * 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
EP2982693A1 (en) * 2014-08-07 2016-02-10 Affimed Therapeutics AG CD3 binding domain
CN109069635B (zh) * 2016-02-04 2023-09-26 斯克利普斯研究所 人源化抗cd3抗体、偶联物及其用途
KR102329635B1 (ko) * 2017-04-24 2021-11-22 재단법인 목암생명과학연구소 Her3 및 cd3에 결합하는 이중특이적 항체

Also Published As

Publication number Publication date
US20200317779A1 (en) 2020-10-08
EA202090944A1 (ru) 2020-07-16
JP2021501571A (ja) 2021-01-21
AU2018353787A1 (en) 2020-05-21
IL274007B1 (en) 2025-04-01
SG11202003273PA (en) 2020-05-28
CN111315779A (zh) 2020-06-19
CN111315779B (zh) 2024-06-21
JP7024072B2 (ja) 2022-02-22
EP3699192A4 (en) 2021-10-20
NZ762975A (en) 2024-07-26
IL274007A (en) 2020-05-31
WO2019078697A8 (ko) 2020-04-09
WO2019078697A2 (ko) 2019-04-25
WO2019078697A3 (ko) 2019-07-04
CA3077007C (en) 2023-04-18
BR112020007770A2 (pt) 2020-10-20
US20230192851A1 (en) 2023-06-22
EP3699192A2 (en) 2020-08-26
IL274007B2 (en) 2025-08-01
KR101973060B1 (ko) 2019-04-26
CA3077007A1 (en) 2019-04-25
US11498965B2 (en) 2022-11-15
AU2018353787B2 (en) 2022-02-24

Similar Documents

Publication Publication Date Title
MX2020003943A (es) Anticuerpo anti-msln y composicion farmaceutica para el tratamiento del cancer que comprende el mismo.
CO2020016559A2 (es) Anticuerpos que se dirigen al gp120 de vih y métodos de uso
EA202091540A1 (ru) Антитела к lilrb2
PH12020500671A1 (en) Antibodies specific for gucy2c and uses thereof
PH12019502875A1 (en) Antibody molecules to cd73 and uses thereof
CL2019001660A1 (es) (aza)indol-, benzotiofen, y benzofuran-3-sulfonamidas.
CL2020000233A1 (es) Anticuerpos anti-cd137.
CO2018010458A2 (es) Composiciones y anticuerpos anti-tim-3
EA202090944A1 (ru) Анти-cd3-антитело и фармацевтическая композиция для лечения онкологических заболеваний, содержащая его
CL2018000222A1 (es) Nueva combinación para el uso en el tratamiento del cáncer
CO2018000104A2 (es) Moléculas de anticuerpo que se unen a cd22
MX2018010295A (es) Anticuerpos que tienen especificidad para atenuador de linfocitos b y t (btla) y usos de los mismos.
CO2021004141A2 (es) Moduladores de la expresión de pnpla3
MX2015016627A (es) Vacuna para la malaria.
CL2020002600A1 (es) Anticuerpo anti-muerte programada-ligando 1 y su uso
CL2017002983A1 (es) Terapia combinada de un anticuerpo anti-cd-20 con un inhibidor de bcl-2 y un inhibidor de mdm2
MX2020003219A (es) Anticuerpos que tienen especificidad para btn2 y usos de los mismos.
AR101312A1 (es) Combinaciones de inhibidores de bet e inhibidores de tirosina quinasa de bruton
PE20201285A1 (es) Cepa vacunal de brucella modificada para el tratamiento de brucelosis
MX2020002585A (es) Inhibidor de hdac combinado con un modulador del punto de control inmunitario para la terapia contra el cancer.
MX2019011124A (es) Anticuerpo anti-ceacam1 y uso del mismo.
BR112018014723A2 (pt) fantasmas bacterianos para o tratamento de câncer
ZA202106807B (en) Antibodies having specificity for btn2 and uses thereof
AR117094A1 (es) Moduladores de expresión irf5
CL2021003442A1 (es) Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer.